CDC25A

M-phase inducer phosphatase 1

52,134 patent compounds predicted against CDC25A, 33,237 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL130160	0.41	9/20
SCHEMBL134428	0.55	8/20
SCHEMBL179749	0.32	8/20
SCHEMBL82554	0.69	7/20
SCHEMBL170030	0.42	6/20
SCHEMBL187581	0.39	6/20
SCHEMBL45540	0.34	6/20
SCHEMBL254004	0.70	5/20
SCHEMBL135273	0.61	5/20
SCHEMBL64776	0.58	5/20
Ubiquinone Qo (SCHEMBL49420)	0.45	5/20
SCHEMBL106015	0.77	4/20
Menadione (SCHEMBL207465)	0.72	4/20
SCHEMBL260558	0.71	4/20
SCHEMBL141358	0.66	4/20
SCHEMBL105206	0.64	4/20
SCHEMBL104504	0.63	4/20
SCHEMBL105651	0.57	4/20
SCHEMBL112795	0.56	4/20
SCHEMBL228422	0.56	4/20

Germline variants in CDC25A on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full CDC25A gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to CDC25A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
Effect of Silymarin in Metastatic Colorectal Cancer Patients	PHASE3	UNKNOWN
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer	PHASE2/PHASE3	NOT_YET_RECRUITING
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression	PHASE3	RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma	PHASE1/PHASE2	COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression	PHASE2	COMPLETED
Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL)	PHASE2	COMPLETED
Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC	PHASE2	COMPLETED
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma	PHASE2	COMPLETED
Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer	PHASE2	COMPLETED
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer	PHASE2	COMPLETED
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors	PHASE1/PHASE2	COMPLETED
Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma	PHASE2	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Study of ABT-751 in Patients With Refractory Hematologic Malignancies	PHASE1	COMPLETED
Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia	PHASE1	WITHDRAWN
Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS)	nan	UNKNOWN
A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction: EXAMINATION Study	nan	COMPLETED
Diagnostic and Prognostic Value of PTEN Expression in Functional and Pathological Endometrial Biopsies	nan	COMPLETED
CircularRNA-microRNA-mRNA Regulatory Axis in IVF	nan	NOT_YET_RECRUITING
Study of Tissue and Blood Samples From Patients With Low-Grade Glioma	nan	COMPLETED
Cyclin-dependent Kinase Inhibitor 2A (Placental Senescence Marker) on Labor-related Signals	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CDC25A binder may also engage these)

Protein	Name	Similarity
A7MBD1	—	1.000	A7MBD1 →
P48964	—	1.000	P48964 →
P48966	—	1.000	P48966 →
P48965	—	1.000	P48965 →
CDC25B	M-phase inducer phosphatase 2	0.998	landscape →
P30306	—	0.994	P30306 →
P30310	—	0.992	P30310 →
Q29029	—	0.991	Q29029 →
CDC25C	M-phase inducer phosphatase 3	0.989	landscape →
A5D7P0	—	0.989	A5D7P0 →
Q9BY84	—	0.989	Q9BY84 →
P30309	—	0.987	P30309 →
P30308	—	0.986	P30308 →
P30311	—	0.985	P30311 →
P48968	—	0.982	P48968 →
P24793	—	0.982	P24793 →
E1BTE1	—	0.980	E1BTE1 →
P48967	—	0.980	P48967 →
Q5QJC2	—	0.980	Q5QJC2 →
Q9R207	—	0.979	Q9R207 →
D2HHP1	—	0.979	D2HHP1 →
Q6P1H6	—	0.979	Q6P1H6 →
Q1LWL8	—	0.979	Q1LWL8 →
E2RSS3	—	0.978	E2RSS3 →
Q28FA8	—	0.978	Q28FA8 →
Q8TEW8	—	0.978	Q8TEW8 →
Q66JT0	—	0.977	Q66JT0 →
A4QNA8	—	0.977	A4QNA8 →
Q6A098	—	0.977	Q6A098 →
Q9JIL9	—	0.977	Q9JIL9 →